World Anti-Microbial Resistance Congress 2023

A world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2020, revenues reached €3.

Over a decade ago, Cepheid set the standard for innovation in automated molecular diagnostics with our first system and we’ve never looked back.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE:R9Q) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superb

Advancing a new class of immunotherapies with targeted fully human polyclonal antibodies for C diff seasonal influenza and Type 1 diabetes without the need for human donors

The AMR Action Fund is a groundbreaking VC fund that enables breakthroughs in the development of antibiotics anti fungals and other antimicrobials We invest in companies developing innovative treatments for priority drug resistant pathogens and advocate for market reforms and policy solutions to cha

AbVacc Inc is a biotechnology company focused on the discovery of novel vaccines and therapeutics for emerging infectious diseases using structure guided design AbVacc s pipeline includes promising product candidates for prevention and treatment of bacterial and viral infections AbVacc s bacterial p

Imagine a world where antibiotics no longer work Unfortunately this is already a reality for many patients as the rise of antimicrobial resistance is rendering antibiotics increasingly ineffective Micreos is a clinical stage pharmaceutical biotech developing medicinal solutions that selectively kill

Acurx Pharmaceuticals is a publicly held clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization Centers for Disease Control and Prevention and Food and Drug Administration

Structural Vaccinology to Prevent Bacterial Infections

La Jolla Pharmaceutical Company a subsidiary of Innoviva Inc is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life threatening diseases La Jolla markets GIAPREZA angiotensin II injection and XERAVA eravacycline for injection For more info

1928 Diagnostics offers a bioinformatics analytics platform for infection control Using sequence data 1928 contributes to the fight against infections by identifying and characterizing pathogens to assist in tracking controlling and preventing outbreaks Our innovation offers a solution to control th